Zacks Research Weighs in on Chemours’ Q1 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Investment analysts at Zacks Research decreased their Q1 2027 earnings per share (EPS) estimates for shares of Chemours in a report issued on Wednesday, July 22nd. Zacks Research analyst Team now expects that the specialty chemicals company will post earnings per share of $0.39 for the quarter, down from their previous forecast of $0.41. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $1.18 per share. Zacks Research also issued estimates for Chemours’ Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The company had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the previous year, the business posted $0.13 earnings per share. Chemours’s quarterly revenue was up 1.0% on a year-over-year basis.

A number of other analysts also recently issued reports on CC. Mizuho cut their price objective on shares of Chemours from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, July 1st. Morgan Stanley raised their target price on shares of Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. UBS Group lifted their price target on shares of Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. boosted their price target on Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Chemours currently has an average rating of “Hold” and a consensus target price of $24.10.

Chemours Price Performance

NYSE:CC opened at $18.24 on Thursday. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82. The firm’s 50-day simple moving average is $20.61 and its 200 day simple moving average is $19.85. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -6.91 and a beta of 1.41.

Institutional Trading of Chemours

Large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in Chemours by 79.1% during the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock valued at $29,014,000 after purchasing an additional 581,621 shares in the last quarter. Edgestream Partners L.P. lifted its stake in Chemours by 1,126.4% during the first quarter. Edgestream Partners L.P. now owns 294,881 shares of the specialty chemicals company’s stock worth $6,496,000 after purchasing an additional 270,836 shares during the last quarter. Amundi acquired a new stake in shares of Chemours in the 1st quarter valued at $272,000. California State Teachers Retirement System boosted its holdings in shares of Chemours by 18.8% in the 1st quarter. California State Teachers Retirement System now owns 173,103 shares of the specialty chemicals company’s stock valued at $3,813,000 after purchasing an additional 27,377 shares in the last quarter. Finally, Quantinno Capital Management LP increased its stake in shares of Chemours by 16.4% in the 1st quarter. Quantinno Capital Management LP now owns 364,745 shares of the specialty chemicals company’s stock valued at $8,035,000 after purchasing an additional 51,275 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio is -13.26%.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.